293 related articles for article (PubMed ID: 37916308)
21. Igniting Hope for Tumor Immunotherapy: Promoting the "Hot and Cold" Tumor Transition.
Wei C; Ma Y; Wang F; Liao Y; Chen Y; Zhao B; Zhao Q; Wang D; Tang D
Clin Med Insights Oncol; 2022; 16():11795549221120708. PubMed ID: 36147198
[TBL] [Abstract][Full Text] [Related]
22. Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule CD73 Inhibitor, Restores Immune Functionality and Facilitates Antitumor Immunity.
Piovesan D; Tan JBL; Becker A; Banuelos J; Narasappa N; DiRenzo D; Zhang K; Chen A; Ginn E; Udyavar AR; Yin F; Paprcka SL; Purandare B; Park TW; Kimura N; Kalisiak J; Young SW; Powers JP; Schindler U; Sivick KE; Walters MJ
Mol Cancer Ther; 2022 Jun; 21(6):948-959. PubMed ID: 35405741
[TBL] [Abstract][Full Text] [Related]
23. Reversing chemokine/chemokine receptor mismatch to enhance the antitumor efficacy of CAR-T cells.
Zhang PF; Wang C; Zhang L; Li Q
Immunotherapy; 2022 Apr; 14(6):459-473. PubMed ID: 35232284
[TBL] [Abstract][Full Text] [Related]
24. Targeting purinergic pathway to enhance radiotherapy-induced immunogenic cancer cell death.
Bao X; Xie L
J Exp Clin Cancer Res; 2022 Jul; 41(1):222. PubMed ID: 35836249
[TBL] [Abstract][Full Text] [Related]
25. Adenosine A2A receptors intrinsically regulate CD8+ T cells in the tumor microenvironment.
Cekic C; Linden J
Cancer Res; 2014 Dec; 74(24):7239-49. PubMed ID: 25341542
[TBL] [Abstract][Full Text] [Related]
26. Blocking LTB
Yan J; Zhu J; Li X; Yang R; Xiao W; Huang C; Zheng C
Phytomedicine; 2023 Oct; 119():154968. PubMed ID: 37531900
[TBL] [Abstract][Full Text] [Related]
27. Adenosine can thwart antitumor immune responses elicited by radiotherapy : Therapeutic strategies alleviating protumor ADO activities.
Vaupel P; Multhoff G
Strahlenther Onkol; 2016 May; 192(5):279-87. PubMed ID: 26961686
[TBL] [Abstract][Full Text] [Related]
28. A defect in KCa3.1 channel activity limits the ability of CD8
Chimote AA; Balajthy A; Arnold MJ; Newton HS; Hajdu P; Qualtieri J; Wise-Draper T; Conforti L
Sci Signal; 2018 Apr; 11(527):. PubMed ID: 29692361
[TBL] [Abstract][Full Text] [Related]
29. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
[TBL] [Abstract][Full Text] [Related]
30. Adenosine in cancer immunotherapy: Taking off on a new plane.
Zhang C; Wang K; Wang H
Biochim Biophys Acta Rev Cancer; 2023 Nov; 1878(6):189005. PubMed ID: 37913941
[TBL] [Abstract][Full Text] [Related]
31. Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules.
Zhou G; Sprengers D; Mancham S; Erkens R; Boor PPC; van Beek AA; Doukas M; Noordam L; Campos Carrascosa L; de Ruiter V; van Leeuwen RWF; Polak WG; de Jonge J; Groot Koerkamp B; van Rosmalen B; van Gulik TM; Verheij J; IJzermans JNM; Bruno MJ; Kwekkeboom J
J Hepatol; 2019 Oct; 71(4):753-762. PubMed ID: 31195061
[TBL] [Abstract][Full Text] [Related]
32. Extracellular purines and their receptors in immunoregulation. Review of recent advances.
Sitkovsky MV
Nihon Ika Daigaku Zasshi; 1998 Oct; 65(5):351-7. PubMed ID: 9808987
[TBL] [Abstract][Full Text] [Related]
33. PI3Kδ/γ inhibitor BR101801 extrinsically potentiates effector CD8
Yoon YN; Lee E; Kwon YJ; Gim JA; Kim TJ; Kim JS
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35288465
[TBL] [Abstract][Full Text] [Related]
34. Unlocking antitumor immunity with adenosine receptor blockers.
Remley VA; Linden J; Bauer TW; Dimastromatteo J
Cancer Drug Resist; 2023; 6(4):748-767. PubMed ID: 38263981
[TBL] [Abstract][Full Text] [Related]
35. A
Kjaergaard J; Hatfield S; Jones G; Ohta A; Sitkovsky M
J Immunol; 2018 Jul; 201(2):782-791. PubMed ID: 29802128
[TBL] [Abstract][Full Text] [Related]
36. Targeting Immunosuppressive Adenosine Signaling: A Review of Potential Immunotherapy Combination Strategies.
Zahavi D; Hodge JW
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240219
[TBL] [Abstract][Full Text] [Related]
37. Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines.
Butt AQ; Mills KH
Oncogene; 2014 Sep; 33(38):4623-31. PubMed ID: 24141774
[TBL] [Abstract][Full Text] [Related]
38. Genetically Induced Tumors in the Oncopig Model Invoke an Antitumor Immune Response Dominated by Cytotoxic CD8β
Overgaard NH; Principe DR; Schachtschneider KM; Jakobsen JT; Rund LA; Grippo PJ; Schook LB; Jungersen G
Front Immunol; 2018; 9():1301. PubMed ID: 29930558
[TBL] [Abstract][Full Text] [Related]
39. Tumor-targeted superantigens produce curative tumor immunity with induction of memory and demonstrated antigen spreading.
Azulay M; Shahar M; Shany E; Elbaz E; Lifshits S; Törngren M; Friedmann A; Kramer R; Hedlund G
J Transl Med; 2023 Mar; 21(1):222. PubMed ID: 36967382
[TBL] [Abstract][Full Text] [Related]
40. DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma.
Fitzgerald AA; Wang S; Agarwal V; Marcisak EF; Zuo A; Jablonski SA; Loth M; Fertig EJ; MacDougall J; Zhukovsky E; Trivedi S; Bhatia D; O'Neill V; Weiner LM
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34737215
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
